Literature DB >> 26179591

Single-Vehicular Delivery of Antagomir and Small Molecules to Inhibit miR-122 Function in Hepatocellular Carcinoma Cells by using "Smart" Mesoporous Silica Nanoparticles.

Changmin Yu1, Linghui Qian1, Mahesh Uttamchandani1, Lin Li1, Shao Q Yao2.   

Abstract

MicroRNAs (miRNAs) regulate a variety of biological processes. The liver-specific, highly abundant miR-122 is implicated in many human diseases including cancer. Its inhibition has been found to result in a dramatic loss in the ability of Hepatitis C virus (HCV) to infect host cells. Both antisense technology and small molecules have been used to independently inhibit endogenous miR-122 function, but not in combination. Intracellular stability, efficient delivery, hydrophobicity, and controlled release are some of the current challenges associated with these novel therapeutic methods. Reported herein is the first single-vehicular system, based on mesoporous silica nanoparticles (MSNs), for simultaneous cellular delivery of miR-122 antagomir and small molecule inhibitors. The controlled release of both types of inhibitors depends on the expression levels of endogenous miR-122, thus enabling these drug-loaded MSNs to achieve combination inhibition of its targeted mRNAs in Huh7 cells.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  bioimaging; drug delivery; mesoporous silica nanoparticles; microRNA; small-molecule inhibitor

Mesh:

Substances:

Year:  2015        PMID: 26179591     DOI: 10.1002/anie.201504913

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  17 in total

Review 1.  Small molecules with big roles in microRNA chemical biology and microRNA-targeted therapeutics.

Authors:  Rengen Fan; Chaocheng Xiao; Xinqiang Wan; Wenzhang Cha; Yufeng Miao; Yong Zhou; Chenglin Qin; Ting Cui; Fenglian Su; Xiangxiang Shan
Journal:  RNA Biol       Date:  2019-04-03       Impact factor: 4.652

Review 2.  MicroRNAs as novel endogenous targets for regulation and therapeutic treatments.

Authors:  Wenzhang Cha; Rengen Fan; Yufeng Miao; Yong Zhou; Chenglin Qin; Xiangxiang Shan; Xinqiang Wan; Ting Cui
Journal:  Medchemcomm       Date:  2017-12-11       Impact factor: 3.597

Review 3.  Applications and perspectives of nanomaterials in novel vaccine development.

Authors:  Yingbin Shen; Tianyao Hao; Shiyi Ou; Churan Hu; Long Chen
Journal:  Medchemcomm       Date:  2017-10-17       Impact factor: 3.597

Review 4.  Nanoparticle-based targeted cancer strategies for non-invasive prostate cancer intervention.

Authors:  Nicholas H Farina; Areg Zingiryan; Michael A Vrolijk; Scott D Perrapato; Steven Ades; Gary S Stein; Jane B Lian; Christopher C Landry
Journal:  J Cell Physiol       Date:  2018-04-16       Impact factor: 6.384

Review 5.  Small molecules targeting microRNA for cancer therapy: Promises and obstacles.

Authors:  Di Wen; Michael Danquah; Amit Kumar Chaudhary; Ram I Mahato
Journal:  J Control Release       Date:  2015-08-06       Impact factor: 9.776

Review 6.  An Analysis of Mechanisms for Cellular Uptake of miRNAs to Enhance Drug Delivery and Efficacy in Cancer Chemoresistance.

Authors:  Justine M Grixti; Duncan Ayers; Philip J R Day
Journal:  Noncoding RNA       Date:  2021-04-16

Review 7.  Getting miRNA Therapeutics into the Target Cells for Neurodegenerative Diseases: A Mini-Review.

Authors:  Ming Ming Wen
Journal:  Front Mol Neurosci       Date:  2016-11-22       Impact factor: 5.639

8.  Placental Homing Peptide-microRNA Inhibitor Conjugates for Targeted Enhancement of Intrinsic Placental Growth Signaling.

Authors:  Frances Beards; Lisa E Jones; Jayne Charnock; Karen Forbes; Lynda K Harris
Journal:  Theranostics       Date:  2017-07-14       Impact factor: 11.556

Review 9.  Mesoporous Silica Nanoparticles as Carriers for Intracellular Delivery of Nucleic Acids and Subsequent Therapeutic Applications.

Authors:  Wenzhang Cha; Rengen Fan; Yufeng Miao; Yong Zhou; Chenglin Qin; Xiangxiang Shan; Xinqiang Wan; Jinbo Li
Journal:  Molecules       Date:  2017-05-11       Impact factor: 4.411

10.  Combined Therapy in Cancer: The Non-coding Approach.

Authors:  Diana Gulei; Ioana Berindan-Neagoe
Journal:  Mol Ther Nucleic Acids       Date:  2018-07-31       Impact factor: 8.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.